MHRA Drug Safety Update - Fluoroquinolone antibiotics: new restrictions and precautions for use due to very rare reports of disabling and potentially long-lasting or irreversible side effects

The MHRA has released a Drug Safety Update regarding new restrictions and precautions for fluoroquinolone antibiotics. 

Disabling, long-lasting, or potentially irreversible adverse reactions affecting musculoskeletal and nervous systems have been reported very rarely with fluoroquinolone antibiotics.

Fluoroquinolone treatment should be discontinued at the first signs of a serious adverse reaction, including tendon pain or inflammation.

Further advice for healthcare professionals and actions to take are available on the MHRA website.